Group 1 - The arbitration court ruled that Regen Biotech, Inc. is prohibited from selling AestheFill in China and must acknowledge that 达透医疗 is the exclusive distributor of the product in the region [1][2] - 达透医疗 has filed for arbitration due to Regen's breach of contract, seeking to confirm the validity of the exclusive agency agreement and claiming initial damages of RMB 1.6 billion, with the right to adjust this amount based on case developments [1] - The arbitration court's decision mandates that Regen must continue supplying AestheFill to 达透医疗 until the final arbitration ruling is made [1] Group 2 - *ST苏吴 stated that the company is currently unable to continue selling AestheFill, and the actual impact will depend on whether Regen complies with the arbitration court's decision [2] - The arbitration court will continue to form an arbitration panel to further review the case, indicating that the final outcome remains uncertain [2]
*ST苏吴孙公司仲裁迎新进展
Zhong Guo Zheng Quan Bao·2025-09-13 08:37